Astria Therapeutics (NASDAQ:ATXS) Now Covered by TD Cowen

Research analysts at TD Cowen started coverage on shares of Astria Therapeutics (NASDAQ:ATXS) in a report released on Monday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $35.00 price target on the biotechnology company’s stock. TD Cowen’s price target points to a potential upside of 206.21% from the company’s current price.

Several other equities analysts have also commented on ATXS. Oppenheimer reduced their target price on shares of Astria Therapeutics from $29.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday, May 21st. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a report on Friday, May 10th. Finally, Wedbush reaffirmed an “outperform” rating and set a $22.00 target price on shares of Astria Therapeutics in a report on Friday, May 10th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $25.00.

Astria Therapeutics Price Performance

Shares of NASDAQ:ATXS opened at $11.43 on Monday. The company’s fifty day moving average price is $9.82 and its 200-day moving average price is $11.25. The firm has a market capitalization of $627.62 million, a price-to-earnings ratio of -4.93 and a beta of 0.74. Astria Therapeutics has a one year low of $4.26 and a one year high of $16.90.

Astria Therapeutics (NASDAQ:ATXS) last issued its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03). As a group, equities research analysts expect that Astria Therapeutics will post -1.56 EPS for the current year.

Institutional Investors Weigh In On Astria Therapeutics

Several institutional investors have recently added to or reduced their stakes in ATXS. RA Capital Management L.P. purchased a new stake in Astria Therapeutics during the 1st quarter valued at $62,115,000. Perceptive Advisors LLC boosted its position in Astria Therapeutics by 82.9% during the 4th quarter. Perceptive Advisors LLC now owns 4,004,070 shares of the biotechnology company’s stock valued at $30,751,000 after buying an additional 1,814,608 shares during the period. Armistice Capital LLC purchased a new stake in Astria Therapeutics during the 4th quarter valued at $12,119,000. Artal Group S.A. purchased a new stake in Astria Therapeutics during the 1st quarter valued at $12,445,000. Finally, Vivo Capital LLC boosted its position in Astria Therapeutics by 47.7% during the 4th quarter. Vivo Capital LLC now owns 2,482,727 shares of the biotechnology company’s stock valued at $19,067,000 after buying an additional 801,528 shares during the period. Hedge funds and other institutional investors own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.